Advancements in specific drug discoveries for targeting MGMT promoters, occurring in glioblastoma, can lead to better prognosis and OS in several cases with MGMT unmethylated tumor cells, i.e. in primary glioblastoma patients. This evidence concerns the gene MGMT and neoplasm.